Chemotherapy for osteosarcoma and Ewing's sarcoma

Acta Orthopaedica Scandinavica, Supplement

Volumn 68, Issue 273, 1997, Pages 120-125

  Saeter G ^a   Aivegard T A ^b   Elomaa, I ^c   Wiebe, T ^b   Bjork O ^d   Strander, H ^d   Solheim, O P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; EWING SARCOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OSTEOSARCOMA; REVIEW; BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; METHODOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; METHOTREXATE; OSTEOSARCOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SARCOMA, EWING'S;

EID: 0031067374     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Harvei S, Solheim Ø. The prognosis in osteosarcoma: Norwegian National data. Cancer 1981; 48: 1719-23.
2. Saner G, Alvegård TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
3. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial SloanKettering experience. J Clin Oncol 1992; 10: 5-15.
4. Winkler K, Bieling P, Bielack S, et al. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatrie Oncology and the Vienna Bone Tumor Registry. Clin Orthop 1991; 79-86.
5. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227-38.
6. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.
7. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-31.
8. Ekert H, Tiedmann K. Osteosarcoma: experience with the Rosen T10 protocol at RCH, Melbourne; in Bennett Humphrey G, Schraffordt Koops H, Molenaar WM, Postma A (eds): Osteosarcoma in adolescents and young adults: new developments and controversies. Boston/ Dordrecht/London, Kluwer Academic Publishers, 1993, pp 355-359.
9. Saeter G. Treatment of Osteosarcoma with high-dose methotrexate-containing neoadjuvant chemotherapy. Scandinavian Sarcoma Group data. Med Ped Oncol 1996; 27: 263.
10. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of Osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-37.
11. Juergens H, Kosloff C, Nirenberg A, et al. Prognostic factors in the response of primary osteogenic sarcoma to preopcrative chemotherapy (high-dose methotrexate with citrovorum factor). Nail Cancer Inst Monogr l981; 56: 221-6.
12. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose melhotrexate, and ifosfamide on histoloaic tumor response in Osteosarcoma (study COSS-86). Cancer 1990; 66: 1703-10.
13. Benjamin RS. Regional chemotherapy for osteosarcoma. Sem Oncol 1989; 16: 264-72.
14. Bacci G, Picci P, Avella M, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologie tumor response of Osteosarcoma of the extremities. J Chemother 1992; 4: 189-95.
15. Benjamin RS, Chawla SP, Carrasco CH, et al. Preopcrative chemotherapy for Osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum. Ann Oncol 1992; 3 Suppl. 2: 3-6.
16. Bielack SS, Bieling P, Entmann R, Winkler K. Intraarterial chemotherapy for Osteosarcoma: does the result really justify the effort? Cancer Treat Res 1993; 62: 85-92.
17. Bielack SS, Entmann R, Looft G, et al. Platinum disposition after intraarterial and intravenous infusion of cisplatin for Osteosarcoma. Cooperative Osteosarcoma Study Group COSS. Cancer Chemother Pharmacol 1989; 24: 376-80.
18. Souhami RL. Chemotherapy for Osteosarcoma. Br J Cancer 1989; 59: 147-8.
19. Goorin A, Gieser P, Schwartzentruber D, et al. No evidence for improved event-free survival with presurgical chemotherapy (pre) for non-metastatic extremity osteosarcoma. Preliminary results of randomized Pediatrie Oncology Group trial 8651, an update. Med Ped Oncol 1996; 27: 263.
20. Salasoo S. Prevention of methotrexate toxicity: effect of infusion rate clearance. Chemoter Oncol 1978; 2: 151-4.
21. Ferrari S, Sassoli V, Orlandi M, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993; 5: 135-41.
22. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51.
23. Delepine N, Delepine G, Comille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15: 489-94.
24. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83: 1460-70.
25. Bacci G, Picci P, Avella M, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 1990; 2: 127-35.
26. Goorin AM, Shuster JJ, Baker A, et al. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991; 9: 600-5.
27. Bacci G, Avella M, Picci P, et al. Metastatic patterns in osteosarcoma. Tumori 1988; 74: 421-7.
28. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084-93.
29. Tabone M-D, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994; 12: 2614-20.
30. Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol 1991; 9: 1357-62.
31. Roth JA, Putnam JBJ, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 1985; 55: 1361-6.
32. Saeter G. Treatment strategies and outcome in metastatic (relapsed) osteogenic sarcoma. The Scandinavian Sarcoma Group (SSG) experience. Med Ped Oncol 1996; 27: 264.
33. Pastorino U, Gasparini M, Azzarelli A, et al. Salvage surgery for childhood osteosarcoma; in Bennett Humphrey G, Schraffordt Koops H, Molenaar \VM, Postma A (eds): Osteosarcoma in children and young adults: new developments and controversies. Boston/Dordrecht/London, Kluwer Academic Publishers, 1993, pp 251-260.
34. l53Sm-EDTMP. Med Ped Oncol 1996; 27: 215.
35. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant Interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995; 34: 877-80.
36. Bruland ØS, Pihl A. Immunoscintigraphy and radioimmunotherapy. Useful approaches in the management of osteogenic sarcoma? In Novak J (ed): Frontiers of osteosarcoma research. Hogrefe and Huber, 1993, pp 149-159.
37. Kleinerman ES, Meyers PA, Raymond AK, et al. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother 1995; 17: 181-93.
38. Sæter G, Bruland ØS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma. The Norwegian Radium Hospital experience during the modem chemotherapy era. Acta Oncol 1996; in press.
39. Bruland OS, Fodstad O, Aas M, et al. Immunoscintigraphy of bone sarcomas - Results in 5 patients. Eur J Cancer [A] 1994; 30A: 1484-9.
40. Sæter G. Treatment of bone and soft tissue sarcomas. The role of chemotherapy, dose-response relationships and haematopoietic growth factors. Gardiner-Caldwell Communications Ltd. 1996.
41. Falk S, Alpen M. Five-year survival of patients with Ewing's sarcoma. Surg Gynecol Obstet 1967; 124: 319-24.
42. Nesbit MEJ, Gehan EA, Burgert EOJ, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first Intergroup study. J Clin Oncol 1990; 8: 1664-74.
43. Burgert EOJ, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990; 8: 1514-24.
44. Bacci G, Picci P, Avella M, et al. Neoadjuvant chemotherapy for localized Ewing sarcoma of bone: experience at the Istituto Ortopedico Rizzoli. Cancer J 1991; 4: 335-42.
45. Sæter G, Alvegård TA, Elomaa I, et al. Multimodality treatment of Ewing's sarcoma according to the SSG IV protocol - a Scandinavian Sarcoma Group Study. Acta Orthop Scand 1996; in press.
46. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European cooperative trial. Cancer 1988; 61: 23-32.
47. Elomaa I, Blomqvist C, Saeter G, et al. Five-year results of the SSG IX protocol in Ewinsi's sarcoma. Med Fed Oncol 1996: 27: 225.
48. Grier H, Krailo M, Link M, et al. Improved outcome in nonmetastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adriamycin (AD), cyclophosphamide (C), and actinomycin (A): a Children's Cancer Group (CCG) and pediatrie Oncology Group (POG) report. Proc Am Soc Clin Oncol 1994; 13: A1443.
49. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochcmotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-8.
50. Marcus Jr RB, Graham-Pole J, Scarborough MT, et al. End-intensification with high-dose chemotherapy, total body irradiation, and autologous bone marrow transplant for hish-risk localized Ewing's sarcoma. Med Ped Oncol 1996; 27: 238.
51. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697-705.